Compare Mesoblast Limited (MESO) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: Global X NASDAQ 100 Covered Call ETF is far larger — about 4.9× Mesoblast Limited's market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Global X NASDAQ 100 Covered Call ETF for 51 Days on average.
| MESO | QYLD | |
|---|---|---|
Market Cap | $1.75B | $8.49B |
Volume | 239,027 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $20.96 | $18.69 |
52-Week Low | $13.19 | $16.70 |
Typical Hold Time | 15 Days | 51 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mesoblast (MESO) trades at $13.75, down 1.36% with bearish technical signals despite recent FDA approval for its Ryoncil potency assay. The company shows significant revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent milestones include completing Phase 3 trials for chronic back pain treatment, positioning the biotech firm for potential market expansion in the $10 billion back pain market.
Investment outlook balances promising commercial progress against persistent financial losses. The stock offers speculative growth potential through FDA-approved therapies and pipeline developments, but carries substantial risk from ongoing cash burn and competitive pressures in the regenerative medicine space.
QYLD trades at $18.66, down slightly by 0.11% on the day, with technical indicators showing a mixed but overall bullish bias. The ETF maintains its covered call strategy on the Nasdaq 100, generating monthly income through option premiums. Recent news highlights concerns about declining option premiums and capital erosion despite the attractive yield.
The outlook remains cautious as QYLD faces headwinds from reduced option premiums and capped upside potential during market rallies. While the 12% yield provides income, long-term investors risk principal erosion and missed growth opportunities compared to the underlying index.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
